These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice. Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959 [TBL] [Abstract][Full Text] [Related]
3. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. Boutajangout A; Ingadottir J; Davies P; Sigurdsson EM J Neurochem; 2011 Aug; 118(4):658-67. PubMed ID: 21644996 [TBL] [Abstract][Full Text] [Related]
4. Tau antibody isotype induces differential effects following passive immunisation of tau transgenic mice. Bajracharya R; Brici D; Bodea LG; Janowicz PW; Götz J; Nisbet RM Acta Neuropathol Commun; 2021 Mar; 9(1):42. PubMed ID: 33712083 [TBL] [Abstract][Full Text] [Related]
5. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. d'Abramo C; Acker CM; Jimenez HT; Davies P PLoS One; 2013; 8(4):e62402. PubMed ID: 23638068 [TBL] [Abstract][Full Text] [Related]
6. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model. Nisbet RM; Van der Jeugd A; Leinenga G; Evans HT; Janowicz PW; Götz J Brain; 2017 May; 140(5):1220-1230. PubMed ID: 28379300 [TBL] [Abstract][Full Text] [Related]
7. Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer's disease. Collin L; Bohrmann B; Göpfert U; Oroszlan-Szovik K; Ozmen L; Grüninger F Brain; 2014 Oct; 137(Pt 10):2834-46. PubMed ID: 25085375 [TBL] [Abstract][Full Text] [Related]
8. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. Castillo-Carranza DL; Gerson JE; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Kayed R J Alzheimers Dis; 2014; 40 Suppl 1():S97-S111. PubMed ID: 24603946 [TBL] [Abstract][Full Text] [Related]
11. Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. Selenica ML; Davtyan H; Housley SB; Blair LJ; Gillies A; Nordhues BA; Zhang B; Liu J; Gestwicki JE; Lee DC; Gordon MN; Morgan D; Dickey CA J Neuroinflammation; 2014 Sep; 11():152. PubMed ID: 25183004 [TBL] [Abstract][Full Text] [Related]
12. Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy. Köhler C; Bista P; Götz J; Schröder H Brain Res; 2010 Aug; 1347():111-24. PubMed ID: 20513372 [TBL] [Abstract][Full Text] [Related]
13. Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies. d'Abramo C; Acker CM; Jimenez H; Davies P PLoS One; 2015; 10(8):e0135774. PubMed ID: 26270821 [TBL] [Abstract][Full Text] [Related]
14. [Passive Tau immunotherapy for prevention of Tau pathology progression]. Ozmen L; Collin L Med Sci (Paris); 2015 Feb; 31(2):132-4. PubMed ID: 25744257 [No Abstract] [Full Text] [Related]
15. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice. Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Boimel M; Grigoriadis N; Lourbopoulos A; Haber E; Abramsky O; Rosenmann H Exp Neurol; 2010 Aug; 224(2):472-85. PubMed ID: 20546729 [TBL] [Abstract][Full Text] [Related]
17. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy. Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295 [TBL] [Abstract][Full Text] [Related]
18. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. Sankaranarayanan S; Barten DM; Vana L; Devidze N; Yang L; Cadelina G; Hoque N; DeCarr L; Keenan S; Lin A; Cao Y; Snyder B; Zhang B; Nitla M; Hirschfeld G; Barrezueta N; Polson C; Wes P; Rangan VS; Cacace A; Albright CF; Meredith J; Trojanowski JQ; Lee VM; Brunden KR; Ahlijanian M PLoS One; 2015; 10(5):e0125614. PubMed ID: 25933020 [TBL] [Abstract][Full Text] [Related]
19. Novel Phospho-Tau Monoclonal Antibody Generated Using a Liposomal Vaccine, with Enhanced Recognition of a Conformational Tauopathy Epitope. Theunis C; Adolfsson O; Crespo-Biel N; Piorkowska K; Pihlgren M; Hickman DT; Gafner V; Borghgraef P; Devijver H; Pfeifer A; Van Leuven F; Muhs A J Alzheimers Dis; 2017; 56(2):585-599. PubMed ID: 28035925 [TBL] [Abstract][Full Text] [Related]
20. Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology. Joly-Amado A; Davtyan H; Serraneau K; Jules P; Zitnyar A; Pressman E; Zagorski K; Antonyan T; Hovakimyan A; Paek HJ; Gordon MN; Cribbs DH; Petrovsky N; Agadjanyan MG; Ghochikyan A; Morgan D Neurobiol Dis; 2020 Feb; 134():104636. PubMed ID: 31629891 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]